Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials

Epidemiology of fragile X syndrome: A systematic review and meta-analysis

(2014) Jessica Hunter et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes

(2014) Christos G. Gkogkas et al.   Cell Reports

High MMP-9 activity levels in fragile X syndrome are lowered by minocycline

(2013) Magdalena Dziembowska et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Autism spectrum disorders: The quest for genetic syndromes

(2013) Dimitrios I. Zafeiriou et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Electrocortical changes associated with minocycline treatment in fragile X syndrome

(2013) Andrea Schneider et al.   JOURNAL OF PSYCHOPHARMACOLOGY

The translation of translational control by FMRP: therapeutic targets for FXS

(2013) Jennifer C Darnell et al.   NATURE NEUROSCIENCE

The FMRP regulon: from targets to disease convergence

(2013) Esperanza Fernández et al.   Frontiers in Neuroscience

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice

(2012) Ilse Gantois et al.   BEHAVIOURAL BRAIN RESEARCH

Altered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome

(2012) C. A. Hoeffer et al.   GENES BRAIN AND BEHAVIOR

Chronic Pharmacological mGlu5 Inhibition Corrects Fragile X in Adult Mice

(2012) Aubin Michalon et al.   NEURON

The trouble with spines in fragile X syndrome: density, maturity and plasticity

(2012) C.X. He et al.   NEUROSCIENCE

Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant

(2012) Andreea S. Pop et al.   PSYCHOPHARMACOLOGY

AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome

(2011) Josien Levenga et al.   NEUROBIOLOGY OF DISEASE

Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056

(2011) S. Jacquemont et al.   Science Translational Medicine

Early continuous inhibition of group 1 mGlu signaling partially rescues dendritic spine abnormalities in the Fmr1 knockout mouse model for fragile X syndrome

(2010) Tao Su et al.   PSYCHOPHARMACOLOGY